Table 2 Biologics as first-line and subsequently, and concomitant therapy in patients with juvenile idiopathic arthritis
Drug | First-line | Second-line or later | Total |
|---|---|---|---|
Etanercept | 204 (43.5) | 119 (25.8) | 323 (34.7) |
Infliximab | 143 (30.5) | 58 (12.6) | 201 (21.6) |
Adalimumab | 89 (19.0) | 108 (23.4) | 197 (21.2) |
Anakinra | 8 (1.7) | 15 (3.3) | 23 (2.5) |
Rituximab | 0 (0.0) | 72 (15.6) | 72 (7.7) |
Abatacept | 5 (1.1) | 28 (6.1) | 33 (3.6) |
Tocilizumab | 16 (3.4) | 40 (8.7) | 56 (6.0) |
Golimumab | 2 (0.4) | 13 (2.8) | 15 (1.6) |
Certolizumab | 2 (0.4) | 5 (1.1) | 7 (0.8) |
Canakinumab | 0 (0.0) | 2 (0.4) | 2 (0.2) |
Ustekinumab | 0 (0.0) | 1 (0.2) | 1 (0.1) |
Use of concomitant drugs | |||
- Monotherapy | 177 (37.7) | 217 (47.1) | 394 (42.4) |
- Methotrexate | 225 (48.0) | 184 (39.9) | 409 (44.0) |
- Glucocorticoids | 155 (33.1) | 145 (31.5) | 300 (32.3) |
- Leflunomide | 29 (6.2) | 26 (5.7) | 55 (5.9) |
- Sulfasalazine | 26 (5.5) | 13 (2.8) | 39 (4.2) |
- Gold salts | 1 (0.2) | – | 1 (0.1) |
- Azathioprine | 3 (0.6) | 5 (1.1) | 8 (0.9) |
- Hydroxychloroquine | 4 (0.9) | 5 (1.1) | 9 (1.0) |